|
EQS-News: M1 Kliniken AG
/ Key word(s): Forecast
M1 Kliniken AG: Management Board confirms growth targets Berlin, 21 June 2024 - As announced on 20 June 2024, Management Board member Attila Strauss has sold part of his stake in M1 Kliniken AG (ISIN: DE000A0STSQ8) for personal financial reasons. Mr Strauss continues to hold a tangible stake of over 2.3% in M1 Kliniken AG. Attila Strauss emphasises: "I understand that such sales can lead to uncertainty and want to assure you that my commitment and belief in the company and the investment is unwavering and long term. I firmly believe that M1 Med Beauty has excellent growth opportunities in the global beauty market. Our latest business figures and forecasts remain strong, with planned sales growth of up to 30% and an increase in EBIT of up to 40% in 2024. Our strategy and strong market position give me great confidence in the future. Together with our dedicated team, we will continue to work on developing M1 Med Beauty into the world's leading private provider of beauty treatments." The Group's medium-term forecast envisages that M1 will operate a total of 150 to 200 specialist medical centres for aesthetic medicine by the end of 2029. The Beauty segment should thus generate revenue of between EUR 200 and 300 million with an EBIT margin of at least 20 %. To put this into perspective: in 2023, the Beauty segment generated revenue of around EUR 70.8 million with 58 locations. About M1 Kliniken AG M1 Kliniken AG is the leading fully integrated provider of aesthetic medical healthcare services in Europe. The Group offers products and services of the highest quality standards in the aesthetic and surgical fields. Beauty medical treatments are currently offered at 62 specialist centres under the "M1 Med Beauty" brand. With six operating rooms and 35 beds, the “M1 Schlossklinik” for Plastic and Aesthetic Surgery in Berlin is one of the largest and most modern facilities of its kind in Europe. M1 Kliniken has been driving forward its internationalisation since the end of 2018 and is currently represented in ten countries. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
21.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1930795 |
| End of News | EQS News Service |
|
|
1930795 21.06.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
